Table 3.

Change in brachial artery flow-mediated dilation with ascorbic acid infusion in participants with autosomal dominant polycystic kidney disease and control participants

Variable	FMDBA with Saline Infusion	FMDBA with Ascorbic Acid Infusion	Change in FMDBA
ADPKD, n=52	7.7±4.5	9.4±5.2	1.72 (0.80 to 2.63)
Control, n=19	10.8±4.7	10.6±5.4	−0.20 (−1.24 to 0.84)

Data are mean±SD or mean (95% confidence interval). P interaction (group × condition) =0.02. FMD_BA, brachial artery flow-mediated dilation; ADPKD, autosomal dominant polycystic kidney disease.